143 related articles for article (PubMed ID: 10939936)
1. AIDS meeting. Companies, donors pledge to close gap in AIDS treatment.
Cohen J
Science; 2000 Jul; 289(5478):368-9. PubMed ID: 10939936
[TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
Chien CV
PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
[TBL] [Abstract][Full Text] [Related]
3. Public health. HIV/AIDS treatment for millions.
Binswanger HP
Science; 2001 Apr; 292(5515):221-3. PubMed ID: 11305311
[No Abstract] [Full Text] [Related]
4. Cut-rate AIDS.
Golden F
Time; 2001 Mar; 157(11):68. PubMed ID: 11276822
[No Abstract] [Full Text] [Related]
5. Global AIDS epidemic: time to turn the tide.
Piot P
Science; 2000 Jun; 288(5474):2176-8. PubMed ID: 10864860
[TBL] [Abstract][Full Text] [Related]
6. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
7. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
Cohen J
Science; 2006 Jul; 313(5786):484-7. PubMed ID: 16873654
[No Abstract] [Full Text] [Related]
8. Profile. Dollars and cents vs. the AIDS epidemic.
Vogel G
Science; 2001 Jun; 292(5526):2420-2. PubMed ID: 11431547
[No Abstract] [Full Text] [Related]
9. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
Sidibé M
Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
[No Abstract] [Full Text] [Related]
10. HIV/AIDS in African children: the Bristol-Myers Squibb Foundation and Baylor response.
Damonti J; Doykos P; Wanless RS; Kline M
Health Aff (Millwood); 2012 Jul; 31(7):1636-42. PubMed ID: 22778353
[TBL] [Abstract][Full Text] [Related]
11. WHO's 3-by-5 target.
Taylor K; DeYoung P
Lancet; 2003 Sep; 362(9387):918. PubMed ID: 13678988
[No Abstract] [Full Text] [Related]
12. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
[TBL] [Abstract][Full Text] [Related]
13. UN political declaration on HIV and AIDS: where to begin?
Poku NK
Lancet; 2016 Aug; 388(10046):743-4. PubMed ID: 27560262
[No Abstract] [Full Text] [Related]
14. Fighting AIDS in Sub-Saharan Africa: is a public- private partnership a viable paradigm?
Clark PA; O'Brien K
Med Sci Monit; 2003 Sep; 9(9):ET28-39. PubMed ID: 12960920
[TBL] [Abstract][Full Text] [Related]
15. South Africa may keep door closed to generic AIDS drugs.
Cherry M
Nature; 2001 Apr; 410(6832):1013. PubMed ID: 11323627
[No Abstract] [Full Text] [Related]
16. AIDS treatment. A step toward cheaper anti-HIV therapy.
Cohen J
Science; 2005 Feb; 307(5710):653. PubMed ID: 15692020
[No Abstract] [Full Text] [Related]
17. Low-cost generic drugs under the President's Emergency Plan for AIDS Relief drove down treatment cost; more are needed.
Venkatesh KK; Mayer KH; Carpenter CC
Health Aff (Millwood); 2012 Jul; 31(7):1429-38. PubMed ID: 22778332
[TBL] [Abstract][Full Text] [Related]
18. AIDS care and treatment in Sub-Saharan Africa: implementation ethics.
Rennie S; Behets F
Hastings Cent Rep; 2006; 36(3):23-31. PubMed ID: 16776020
[TBL] [Abstract][Full Text] [Related]
19. Indian company seeks US approval for generic AIDS drugs.
Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
[No Abstract] [Full Text] [Related]
20. United Nations. Global program struggles to stem the flood of new cases.
Balter M
Science; 1998 Jun; 280(5371):1863-4. PubMed ID: 9669942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
